342 related articles for article (PubMed ID: 10389286)
1. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC
Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286
[TBL] [Abstract][Full Text] [Related]
2. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.
Baracat EC; Barbosa IC; Giordano MG; Haidar MA; Marinho RM; Menegocci JC; Morais KM; Tomaz G; Wehba S
Climacteric; 2002 Mar; 5(1):60-9. PubMed ID: 11974560
[TBL] [Abstract][Full Text] [Related]
3. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
[TBL] [Abstract][Full Text] [Related]
4. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Langer RD; Landgren BM; Rymer J; Helmond FA;
Am J Obstet Gynecol; 2006 Nov; 195(5):1320-7. PubMed ID: 16875644
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables.
Siseles NO; Halperin H; Benencia HJ; Berg G; Pilnik S; Mesch V; Arrighi B; Wikinski RW
Maturitas; 1995 Apr; 21(3):201-10. PubMed ID: 7616869
[TBL] [Abstract][Full Text] [Related]
6. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
[TBL] [Abstract][Full Text] [Related]
7. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
8. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women.
Osmanağaoğlu MA; Osmanağaoğlu S; Osmanağaoğlu T; Okumuş B; Bozkaya H
Fertil Steril; 2005 Aug; 84(2):384-93. PubMed ID: 16084879
[TBL] [Abstract][Full Text] [Related]
9. Flow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy.
Pan HA; Wang ST; Chen CH; Pai MC; Wu MH; Huang KE
Climacteric; 2002 Sep; 5(3):259-65. PubMed ID: 12419084
[TBL] [Abstract][Full Text] [Related]
10. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy.
Wu MH; Pan HA; Wang ST; Hsu CC; Chang FM; Huang KE
Climacteric; 2001 Dec; 4(4):314-9. PubMed ID: 11770188
[TBL] [Abstract][Full Text] [Related]
11. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
Ziaei S; Moghasemi M; Faghihzadeh S
Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
[TBL] [Abstract][Full Text] [Related]
13. Endometrial effects of tibolone.
Archer DF; Hendrix S; Gallagher JC; Rymer J; Skouby S; Ferenczy A; den Hollander W; Stathopoulos V; Helmond FA
J Clin Endocrinol Metab; 2007 Mar; 92(3):911-8. PubMed ID: 17192288
[TBL] [Abstract][Full Text] [Related]
14. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
Gallagher JC; Kable WT; Goldgar D
Am J Med; 1991 Feb; 90(2):171-8. PubMed ID: 1847582
[TBL] [Abstract][Full Text] [Related]
15. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women.
Castelo-Branco C; Vicente JJ; Figueras F; Sanjuan A; Martínez de Osaba MJ; Casals E; Pons F; Balasch J; Vanrell JA
Maturitas; 2000 Feb; 34(2):161-8. PubMed ID: 10714911
[TBL] [Abstract][Full Text] [Related]
16. Combined continuous hormone replacement therapy: a critical review.
Udoff L; Langenberg P; Adashi EY
Obstet Gynecol; 1995 Aug; 86(2):306-16. PubMed ID: 7617369
[TBL] [Abstract][Full Text] [Related]
17. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints.
Egarter C; Huber J; Leikermoser R; Haidbauer R; Pusch H; Fischl F; Putz M
Maturitas; 1996 Feb; 23(1):55-62. PubMed ID: 8861087
[TBL] [Abstract][Full Text] [Related]
18. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B.
Castelo-Branco C; Casals E; Figueras F; Sanjuan A; Vicente JJ; Balasch J; Vanrell JA
Menopause; 1999; 6(2):92-7. PubMed ID: 10374214
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women.
Diaby V; Perreault S; Lachaine J
Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259
[TBL] [Abstract][Full Text] [Related]
20. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
